PhRMA PRESENTS THE 2015

Research & Hope Awards

Celebrating Progress,
Building on Research,
Providing Hope

SEPTEMBER 9, 2015  |  WASHINGTON, D.C.
This year’s honorees and their inspiring stories are presented on the following pages.

We commend, congratulate and celebrate their outstanding contributions.

A VERY SPECIAL THANK YOU TO OUR CO-HOSTS:
Welcome to the 2015 Research & Hope Awards, which celebrate research breakthroughs that deliver increasing hope to America’s patients and their families.

This year’s awardees are pioneers working at the leading edge of cancer science, accelerating and applying this advanced knowledge so that we can better assess and treat this broad range of diseases – or beat them.

These Research & Hope Awards are presented this evening in five categories:

- **Academic Research**: Presented to individuals or a team from the academic community for outstanding cancer research;

- **Biopharmaceutical Industry Research**: Presented to individuals or a team from a biopharmaceutical research company for outstanding cancer research;

- **Excellence in Advocacy & Activism**: Presented to an individual or organization that has made a significant impact supporting and advocating for legislative or regulatory health policy issues specific to cancer. Their work has increased awareness, funding for research or access to care. The award recognizes the involvement, commitment and achievement in promoting the importance of research for and access to cancer treatments and therapies;

- **Community Champion**: Presented to an individual or organization that has made a significant impact advocating for the cancer community to policymakers, community leaders and health organizations with the goal of helping people with cancer live healthier, independent lives;

- **Visibility & Progress**: Presented to an individual or organization that has made a significant impact on public education and awareness of cancer prevention, progress in research and policies impacting people living with cancer.

Our common fight against cancer is as relentless as it is essential. Thank you for joining us in celebrating true pioneers helping to lead that fight.

John J. Castellani
President and Chief Executive Officer, PhRMA
SCHEDULE

2015 RESEARCH & HOPE AWARDS DINNER

WEDNESDAY, SEPTEMBER 9, 2015 - 6 PM

RECEPTION

DINNER SEATING

Welcome Remarks from PhRMA’s Chairman of the Board of Directors
Kenneth C. Frazier

Dinner Service

KEYNOTE ADDRESS:
Tom Brokaw
Legendary Newsman, NBC News and The New York Times Best-selling Author

AWARDS PRESENTATION
Tom Brokaw

Tom Brokaw has spent his entire distinguished journalism career with NBC News beginning in 1966 in the Los Angeles bureau where he covered Ronald Reagan’s first run for public office, the rise of the Sixties counter culture, the assassination of Bobby Kennedy and the 1968 presidential campaign.

From Los Angeles, Brokaw went to Washington as the White House correspondent during Watergate and as the principal back up for John Chancellor as anchor of NBC Nightly News. Next stop: New York and TODAY followed by his appointment as anchor and managing editor of NBC Nightly News with Tom Brokaw.

He took over Meet the Press for the 2008 campaign when his close friend and colleague Tim Russert died.

In addition to his daily news gathering responsibilities, Brokaw reported on more than thirty documentaries covering subjects ranging from AIDS, Los Angeles gangs, race, education, medicine, immigration and global warming.

He has an impressive list of firsts, including the first interview with Mikhail Gorbachev; the first network report on human rights abuses in Tibet accompanied by an exclusive interview with the Dalai Lama; the only American network anchor to report from Berlin the night the Berlin Wall came down.

In 1998, Brokaw published his first book, The Greatest Generation, one of the most popular non-fiction books of the 20th century. He followed that with five other books, including BOOM! Voices Of The Sixties and The Time Of Our Lives.

He is also a popular essayist for publications ranging from The New York Times to Rolling Stone and a wide assortment of other periodicals and newspapers.

Brokaw’s latest book is A Lucky Life Interrupted (May 2015). In this powerful memoir of a year of dramatic change, the best-selling author and former NBC anchorman chronicles a year spent battling cancer and reflecting on his long, lucky life.
Historians believe a pre-1500 B.C. Egyptian textbook documents the first written record of cancer. And while the author describes rudimentary means of removing tumors of the breast, he uses far fewer words when detailing a general prognosis, concluding: “There is no treatment.”

After thousands of years — and millions of treatments for global patients — researchers continue rewriting history.

In the United States in 2015, cancer death rates are down 22 percent from their peak in 1991 and the five-year survival rate is 68 percent. Since the mid-1970’s, survival rates for childhood cancers increased 43 percent. Since 1975, the five-year survival rate increased 21 percent for breast cancer; 51 percent for prostate cancer; 37 percent for colon cancer; and 60 percent for lung cancer.

As these astounding numbers show, new treatments have improved the outlook for many patients. Last year that progress continued: in 2014, the U.S. Food and Drug Administration (FDA) approved nine new anticancer therapeutics. Many of these medicines target the root cause of cancers at the molecular level and some harness the body’s immune system to attack cancer cells.

In 2015, America’s biopharmaceutical research companies are developing 836 new medicines and vaccines for cancer, all of which are in clinical trials or awaiting review by the FDA. While more medicines are in development and more are reaching patients, many do not. These so-called “failures” dot the biopharmaceutical pipeline, yet they remain an expected and critical part of the discovery process. Researchers use the knowledge gained from such setbacks to better understand cancer and inform subsequent research on other medicines in development.

This process is demonstrated in the analysis of three difficult-to-treat cancers — melanoma, lung cancer and brain cancer. Since 1998, there have been 96 unsuccessful attempts to develop drugs to treat melanoma, 167 for lung cancer and 75 for brain cancer. In the same period, new medicines beat the odds and advanced care: seven new drugs to treat melanoma, ten for lung cancer and three for brain cancer were approved by the FDA.

These numbers underscore the challenges of the process, but also the hard work, talent and dedication that it takes to get to breakthroughs. Although cancer continues to be a major challenge, biopharmaceutical companies are dedicated to transforming the outlook for cancer patients from a devastating diagnosis to a chronic, manageable condition — and we recognize our partners throughout the cancer research community who are working together toward that same goal.

The women and men, researchers, practitioners and advocates honored with the 2015 Research & Hope Awards deserve recognition and our gratitude for their contributions in seeking to discover innovative medicines that bring hope to patients and their families.

When we discuss cancer today, the hard work of these women and men and others across time and place enables us to say: there is treatment. Every year, we gain new knowledge about this disease’s many types. New tools are created, new medicines developed and new treatments emerge.

We all seek an end to cancer. Every year, we come a little bit closer.

1 ACS The History of Cancer
Innovative cancer medicines developed by biopharmaceutical research companies have led to an increase in patient survival rates and higher life expectancy around the world. Learn about the current human and economic impact that cancer imposes on the U.S. and the progress that is being made toward fighting cancer and understanding the value of its therapies.

**Value of Cancer Medicines**

**Human & Economic Impact**

**The Burden of Cancer**
In 2015, more than 1.6 million new cancer cases are expected to be diagnosed, and an estimated 589,430 people are expected to die of cancer.

*Source: American Cancer Society*

**Spending on Cancer Medicines**
Spending on cancer medicines represents less than 1% of overall health care spending.

*Source: KPS Institute for Healthcare Informatics*

**Major Gains in the Fight Against Cancer: Falling Death Rates**
The cancer death rate has fallen 22% from its peak in 1991, in large part due to medicines.

*Source: American Cancer Society*

**Major Gains in the Fight Against Cancer: Benefiting our Youth**
Survival rates for childhood cancers have increased 43% over the last several decades.

*Source: American Cancer Society*

**Our Society as a Whole Benefits from Medical Progress**

**Major Gains in Life Expectancy**
More than 23 million years of collective life have been saved through cancer treatment advances between 1988 and 2000.

*Source: D'V Leidywoman, et al.*

**Savings in Overall Health Care Costs**
The value of cancer treatment between 1988 and 2008 amounted to $1.3 trillion based on improved productivity, extended life, and other factors.

*Source: D'V Leidywoman, et al.*

**Greater Understanding = Greater Progress**
100 years ago leukemia and lymphoma were considered to be one disease but today the two encompass about 100 individual diseases that scientists are tackling with greater precision.

**The Future is Bright**

**Thousands of Novel Treatments on the Horizon**
73% of cancer medicines in the pipeline have the potential to be personalized medicines.

*Source: Tufts Center for the Study of Drug Development*
J. Silvio Gutkind, Ph.D.

Dr. J. Silvio Gutkind received his Doctor of Pharmacy and Biochemistry from the University of Buenos Aires, Argentina. He was trained as a post-doctoral fellow at the National Institute of Mental Health and National Cancer Institute, and joined the National Institute of Dental and Craniofacial Research, NIH, where he is currently the chief of the Oral and Pharyngeal Cancer Branch. Gutkind is a national and international leader in the study of basic signal transduction mechanisms in cancer. He is recognized for his pioneering research aimed at unraveling the complexity of the intracellular signaling circuitry by which cell surface receptors and Rho GTPases control the nuclear expression of growth promoting genes, thereby promoting normal and malignant growth. His recent studies have addressed the role of mutant G proteins and G protein coupled receptors in cancer initiation, with emphasis on ocular melanoma, colon and skin cancer, and AIDS-malignancies. His multidisciplinary team has also made outstanding contributions to the study of the aberrant signaling circuitries driving head and neck cancer progression, including the seminal finding that most head and neck cancer lesions display persistent activation of the PI3K–AKT–mTOR pathway. His team is now exploiting the emerging information for the development of novel mechanism-based anti-cancer therapies. In particular, Gutkind is currently leading a multi-institutional effort aimed at exploring the clinical benefits of treating newly diagnosed head and neck cancer patients with mTOR inhibitors. He has been the recipient of numerous awards, edited three books, and published more than 400 research studies and review articles in prestigious journals. He has organized multiple national and international meetings and symposia, and he is a member of numerous editorial boards of scientific journals and national and international advisory committees. He has supervised and mentored many junior investigators, who are now playing leadership roles in multiple institutions in the U.S. and abroad.
Scot Ebbinghaus, MD

Dr. Scot Ebbinghaus has made a lifelong commitment to cancer research and finding new treatments for cancer. Currently, Ebbinghaus is in clinical research at Merck, where he leads the product development team for pembrolizumab (KEYTRUDA®) in melanoma. Ebbinghaus has been involved in cancer research and the discovery or development of new treatment strategies for cancer for 25 years since the beginning of his residency. After completing an academic internal medicine residency and hematology/oncology at the University of Alabama-Birmingham, Ebbinghaus held faculty positions at the University of Alabama-Birmingham and the University of Arizona, where he focused on molecular biology research in addition to patient care and clinical research. Ebbinghaus joined Merck in 2007 and has been the clinical lead for two important programs spanning Phase I to III clinical research.

Most recently, Ebbinghaus played a key role in the development of the anti-PD-1 antibody, pembrolizumab, a new immunotherapy for cancer that was designated as a breakthrough therapy by the U.S. Food and Drug Administration in 2013 and approved on an accelerated basis in 2014 for the treatment of patients with melanoma. Ebbinghaus is committed to seeking regulatory approvals to make this important new drug available to cancer patients around the world and to finding future combination strategies to further improve on this important breakthrough.

Gregory Michael Lubiniecki, MD

Dr. Gregory Michael Lubiniecki is a senior principal scientist at Merck Research Laboratories where he has been employed for more than seven years in oncology clinical research. Lubiniecki has worked on many clinical trials ranging from Phase I to III and has been a product development team leader and oncology investigator studies chair. Lubiniecki has worked to register Zolinza and KEYTRUDA® in various international markets.

Lubiniecki earned his medical degree from the Johns Hopkins School of Medicine and attended the Mayo Graduate School of Medicine for his internship and residency in internal medicine. He completed his hematology and medical oncology fellowship training at the University of Pennsylvania. Lubiniecki sees patients with thoracic malignancies at the Temple Fox Chase Cancer Center in Philadelphia.
Eric Rubin, MD

Dr. Eric Rubin’s interest in cancer therapeutics began as an oncology fellow and faculty member at the Dana-Farber Cancer Institute. It was there where he studied DNA topoisomerase I as a target, and was the first to demonstrate that resistance to topoisomerase I-targeting drugs occurs through mutations that affect DNA binding by the enzyme. He was recruited subsequently to lead the Investigational Therapeutics Division at the Cancer Institute of New Jersey (CINJ), Robert Wood Johnson Medical School. At this institution he led both drug discovery and development activities. Under his leadership, CINJ obtained a Phase I Trials Contract with the National Cancer Institute (NCI), and collaborated with several pharmaceutical companies in the development of anti-cancer drugs with varied mechanisms of action. His laboratory also cloned a novel topoisomerase I- and p53-interacting tumor suppressor gene, TOPORS.

In 2008, Rubin was recruited to Merck as vice president and therapeutic area head of oncology clinical research. He led the development of the anti-PD-1 antibody pembrolizumab, which was the first PD-1 inhibitor approved in the U.S., and in the identification of the significant activity of this antibody across several additional tumor types. Under his leadership, the Merck oncology group underwent a transformational change in an effort to realize the potential of cancer immunotherapy, more than doubling in size from 2008 to 2015, and increasing the number of clinical studies of pembrolizumab from one in 2011 to more than 70 in 2015.

Rubin has authored more than 100 original, peer-reviewed publications and book chapters. He has served frequently on NCI and American Cancer Society study sections, as well as on program committees for the American Association for Cancer Research and the American Society of Clinical Oncology. In addition, he serves on several editorial boards, and is a deputy editor for *Clinical Cancer Research*. Rubin obtained his medical degree from the University of South Florida and completed residency at Yale-New Haven Hospital.

Kevin Gergich, M.A.

Kevin Gergich began his career in Clinical Research in 1999, joining Merck in 2000. From 2000 through 2009, he worked in several therapeutic areas including cardiovascular, respiratory and vaccine clinical development. In 2009, Gergich transitioned to Merck Oncology and from 2010 has been supporting the development of KEYTRUDA®, a new immunotherapy for the treatment of cancer (anti-PD-1 antibody). In this capacity, he supports KEYTRUDA’s® clinical development programs in both melanoma and non-small cell lung cancer. Gergich played an important role in the development and accelerated approval of this breakthrough therapy in 2014 for the treatment of melanoma.
Kenneth Emancipator, MD, DABP

Dr. Kenneth Emancipator is a nationally-renowned pathologist who currently leads all companion diagnostics programs at Merck Research Laboratories and serves on the board of directors of the American Society for Clinical Pathology. He is also a regular reviewer for the American Journal of Clinical Pathology. He has in-depth experience with in vitro diagnostics from every perspective, having served previously as medical director both for academic clinical laboratories and for diagnostics manufacturers, and having been a reviewer for the U.S. Food and Drug Administration.

Emancipator received his A.B. degree from Harvard University and his MD from St. Louis University. He completed his medical internship at Westchester County Medical Center and his pathology residency at the State University of New York at Stony Brook. Prior to joining Merck in 2011, he held appointments at the U.S. National Institutes of Health, Cornell University, Beth Israel Medical Center, Bayer Healthcare, Siemens Healthcare and Abbott Molecular. He also has held various leadership positions with ASCP since 1994. He has published 86 articles and abstracts and has given 90 extramural presentations.

Emancipator’s primary interest has always been the role of diagnostic tests in driving clinical decisions. His current focus is personalized medicine and precision diagnostics, with a special emphasis in oncology. When not in his office at Merck, he is most likely to be found along the beaches and coastal waterways of Eastern Long Island.

Gargi Maheshwari, Ph.D.

Dr. Gargi Maheshwari started her career at Merck Research Laboratories in 2000, in the vaccine bioprocess research and development area. While there, she worked on all aspects of upstream bioprocess development of mammalian cell culture based viral vaccines. She was part of the team responsible for development of the manufacturing process for the adenovirus based HIV vaccine product in Phase II clinical development. Following that, Maheshwari and her team were responsible for the development of the second generation Varicella bulk manufacturing process, enabling the manufacture of Varicella containing vaccines, Zostavax and ProQuad, now a billion dollar franchise. She led the technology transfer of this process into manufacturing, and won the inaugural Merck’s prestigious Chairman’s Cup award in 2013 for this effort.

Maheshwari moved to Merck Manufacturing Division in 2009, to support establishment of the biologics commercialization area. Through May 2013, she led the process development and commercialization department in Biologics Manufacturing Sciences & Commercialization, managing teams at multiple sites, and was responsible for late stage bioprocess development for biologics. As the co-lead of the Integrated Development and Supply Team for KEYTRUDA®, she is currently responsible for managing the chemistry manufacturing and controls aspects of KEYTRUDA®, accelerating the product through development stages to commercialization, in response to the breakthrough therapy designation from the U.S. Food and Drug Administration.

Maheshwari received a Ph.D. degree in Chemical Engineering from the Massachusetts Institute of Technology where she was awarded the Poitras fellowship for outstanding biomedical engineering research. She graduated at the top of her class and was awarded the President’s Silver Medal in receiving her Bachelor and Master of Technology degrees in Biochemical Engineering and Biotechnology from the Indian Institute of Technology, Delhi. Maheshwari has more than 15 peer reviewed publications, has authored numerous internal Merck technical product reports, and has presented many invited lectures and chaired sessions at international technical conferences.
Victoria Reggie Kennedy

Victoria Reggie Kennedy is an attorney and consultant. Through VR Kennedy Strategies LLC, she advises clients and assists them in devising strategies to resolve complex business problems, particularly those stemming from regulatory, communications or governance concerns. Additionally, she assists clients in navigating federal administrative processes, as well as in developing and executing strategies to expand their impact in the marketplace.

Kennedy is the president of the board and co-founder of the Edward M. Kennedy Institute for the United States Senate in Boston, a non-partisan organization created to educate the public about the unique role of the United States Senate in our democracy. The mission of the organization is to invigorate public discourse, encourage participatory democracy and inspire the next generation of citizens and leaders. Through innovative and interactive high technology programming as well as a full-scale recreation of the Senate Chamber, visitors to the Institute experience the unique role of the U.S. Senate in our democracy and have the opportunity to experience in a hands on way what it means to be a U.S. Senator.

Kennedy previously was a partner at Keck, Mahin and Cate, a large, multi-city, Chicago-based law firm. The focus of her legal practice was the representation of commercial banks and savings and loans for compliance. Her practice also involved the successful restructure and renegotiation of complex loan transactions on behalf of both banks and borrowers. She began her legal career as a law clerk for Judge Robert Sprecher in the U.S. Court of Appeals for the Seventh Circuit in Chicago.

She is a trustee of the John F. Kennedy Center for the Performing Arts (Presidential appointment) where she chairs its education committee and is a member of the board of overseers of the Museum of Fine Arts Boston. She is a member of the board of directors of the National Leadership Roundtable on Church Management, a lay initiative to assist Catholic Church parishes, church organizations and religious orders promote excellence and best practices in management, finances and human resource development.

She is a member of the Commission on Political Reform, a project of the Bipartisan Policy Center launched in March 2013 to investigate the causes and consequences of America’s partisan political divide and to advocate for specific reforms.

In 2014, Kennedy was nominated by President Barack Obama to the board of governors of the U.S. Postal Service and was unanimously approved by the Senate Committee on Homeland Security. The full Senate adjourned at year-end without taking action.

Kennedy has been a long-time advocate for the protection of children, particularly gun violence prevention. She was the co-founder and past president of Common Sense About Kids and Guns, a diverse coalition of gun control advocates, health professional and gun manufacturers working together to reduce gun deaths and injuries to children in the United States. She is also a past 10-year member of the board of directors of the Brady Center to Prevent Gun Violence.
In addition to her legal and consulting career, board service and non-profit leadership roles, Kennedy has served in key strategic and political roles on issues ranging from health and education to labor, especially as those issues affect women and children, and she advocates for involvement in the political process. Kennedy was actively involved in the passage of the Affordable Care Act of 2010 and stood at President Obama’s side at the signing of the bill into law.

She has received numerous awards including Honorary Doctorates from Boston University, Northeastern University, Montclair State University, University of Massachusetts Boston, Lesley University, Emmanuel College, Western New England University and Suffolk University Law School. She has been honored as a distinguished professor and mentor at the University of Massachusetts Boston.

Kennedy received a J.D., summa cum laude, from Tulane University School of Law, in New Orleans. She was a member of the board of editors and the notes editor of the Tulane Law Review. She earned a B.A. in English, magna cum laude, from Newcomb College at Tulane University and was elected to Phi Beta Kappa.
Rick Dunetz

Rick Dunetz is the founder and executive director of The Side-Out Foundation. His love for volleyball drew him to the world of coaching in 2002, and he hasn’t left the courts since. He was the assistant coach of the West Springfield High School girls volleyball team from 2002-2003, before assuming the head coach position from 2004 through 2007. In that time, “Coach D” led the Spartans to the district finals every year, once to win their first championship which sent them to the regional semifinals (2004).

Dunetz’s 2004 team was special. When they learned that his mom was diagnosed with breast cancer for the second time – this time with an incurable form – the players rallied around their coach and worked hard to overcome their underdog status. Dunetz’s mom, Gloria, found inspiration in their determination and courage. A high school volleyball team helped to give her the strength to learn more about her diagnosis of metastatic breast cancer and overcome fear of what the future held.

In 2005, Dunetz decided to harness the strength and heart of his 2004 team and do something to inspire other volleyball players to connect with the breast cancer cause. That summer, he started The Side-Out Foundation and hosted a grass volleyball tournament to raise funds for breast cancer research supporting people fighting the latest stage of the disease. At the tournament’s peak, it fielded 300 teams on 50 nets and raised more than $60,000.

In 2008, he followed his passion and quit his day job to support the foundation fulltime. It was clear that in order to make a big impact with The Side-Out Foundation, he must find a way to connect to the volleyball community at a national level. After some initial research, he saw some interesting things happening around the country where educational institutions were dedicating one of their matches to raise funds and awareness for different causes and donating those funds to various charities. In the first part of the that year, Dunetz pulled together a database of 20,000 volleyball coaches and sent general emails asking them to unite under the breast cancer cause and dedicate the funds to a single goal: to change the way breast cancer is treated forever.

Today, 3,000 volleyball teams throughout the U.S. and overseas host Dig Pink® events to teach and inspire communities to join The Side-Out Foundation in their mission. More than $9 million has been raised since 2008, and the funds are supporting cutting edge breast cancer research that is focused on personalized medicine for breast cancer patients with metastatic disease. The results have been shared with oncologists and scientists around the world. Dunetz’s mom lived with stage 4 breast cancer for six years and cheered at many a volleyball game before her death in 2010. Every milestone The Side-Out Foundation reaches is celebrated in her memory. She remains Side-Out’s inspiration and motivation.

Prior to establishing his presence in the sport of volleyball, Dunetz worked in the technology industry where he mastered the art of data mining, still one of his favorite pastimes. He enjoys pushing the limits of all things computer-related and is dedicated to utilizing his skills to make a difference for breast cancer patients and their families. He lives in Northern Virginia with his wife, Akiyo, and their two cats.
Liz Scott

Liz Scott is the co-executive director of the Alex’s Lemonade Stand Foundation, but she is most proud of her title of “Mom” to her three sons, Patrick, Eddie, and Joey, and her daughter, Alex, Lemonade Stand’s founder. When Alex decided to hold a lemonade stand to help other children like her with cancer, Scott and her husband, Jay, were happy to serve as her helpers. Along with helping Alex host her yearly lemonade stands, Scott and her family soon found themselves answering emails and phone calls, planning fundraising events, and helping to organize the early grassroots efforts of Alex’s Lemonade Stand. Today, Scott is honored to work alongside her husband, the staff and board of directors, as well as the dedicated sponsors and supporters as they continue to fight childhood cancer, one cup at a time. Scott is frequently sought after to speak to a variety of groups including businesses, schools and community groups, in addition to participating on panels at national conferences. She tailors her presentation to the audience whether they are individuals at the United Nations, students at the University of Pennsylvania Medical School or elementary school children and their parents. Her speaking topics include the story of Alex as the impetus for Alex’s Lemonade Stand Foundation; how to make a difference and meaningful impact; the power of one; caregiving for a child with cancer and other topics related to Alex and her inspiration.

Jay Scott

Jay Scott is the co-executive director of Alex’s Lemonade Stand Foundation. When his daughter Alexandra “Alex” Scott decided to hold a lemonade stand to help doctors find new treatments and ultimately a cure for all childhood cancers, including her own, Scott and his wife, Liz, supported her mission every step of the way. After cancer took Alex’s life they continued her legacy of hope. What started as the vision of one little girl has been embraced by a team of 100,000 volunteers. Scott speaks frequently to groups including businesses, schools and community groups, in addition to participating on panels at national conferences. His speaking topics include the story of Alex as the impetus for Alex’s Lemonade Stand Foundation; how to make a difference and meaningful impact; the power of one; caregiving for a child with cancer and other topics related to Alex and her inspiration. Scott also often speaks about how to create a following on social media and utilizing this platform for successful outreach. He has experience addressing a variety of audiences and tailors his presentation to resonate with individuals of all walks of life ranging from the United Nations and University of Pennsylvania Medical School students to elementary school children and their parents.
American Association for Cancer Research

The mission of the American Association for Cancer Research (AACR) is to prevent and cure cancer through research, education, communication and collaboration. Through its programs and services, the AACR fosters research in cancer and related biomedical science; accelerates the dissemination of new research findings among scientists and others dedicated to the conquest of cancer; promotes science education and training; and advances the understanding of cancer etiology, prevention, diagnosis and treatment throughout the world.

Founded in 1907, the American Association for Cancer Research is the world’s oldest and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR membership includes more than 34,000 laboratory, translational and clinical researchers; population scientists; other health care professionals; and cancer advocates residing in more than 90 countries. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, biology, diagnosis and treatment of cancer by annually convening more than 20 conferences and educational workshops, the largest of which is the AACR Annual Meeting with more than 18,000 attendees. In addition, the AACR publishes eight peer-reviewed scientific journals and a magazine for cancer survivors, patients, and their caregivers. The AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the scientific partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration and scientific oversight of team science and individual grants in cancer research that have the potential for near-term patient benefit. The AACR actively communicates with legislators and lawmakers about the value of cancer research and related biomedical science in saving lives from cancer. For more information about the AACR, visit www.AACR.org.

American Cancer Society Cancer Action Network

American Cancer Society Cancer Action Network (ACS CAN) is the nonprofit, nonpartisan advocacy affiliate of the American Cancer Society, supports evidence-based policy and legislative solutions designed to eliminate cancer as a major health problem. ACS CAN works to encourage elected officials and candidates to make cancer a top national priority. ACS CAN gives ordinary people extraordinary power to fight cancer with the training and tools they need to make their voices heard. For more information, visit www.acscan.org.
American Lung Association
The American Lung Association is the leading organization working to save lives by improving lung health and preventing lung disease, through research, education and advocacy. The work of the American Lung Association is focused on four strategic imperatives: to defeat lung cancer; to improve the air we breathe; to reduce the burden of lung disease on individuals and their families; and to eliminate tobacco use and tobacco-related diseases. LUNG FORCE is a new national movement led by the American Lung Association to unite women against lung cancer, the No. 1 cancer killer of women. LUNG FORCE has three priorities: 1) Make lung cancer a cause that people care about — and act on; 2) Educate and empower patients and healthcare providers and 3) Raise critical funds for lung cancer research. The American Lung Association’s LUNG FORCE is nationally presented by CVS Health.

American Society for Radiation Oncology
American Society for Radiation Oncology (ASTRO) is the premier radiation oncology society in the world, with more than 10,000 members who are physicians, nurses, biologists, physicists, radiation therapists, dosimetrists and other health care professionals that specialize in treating patients with radiation therapies. As the leading organization in radiation oncology, the Society is dedicated to improving patient care through professional education and training, support for clinical practice and health policy standards, advancement of science and research and advocacy. ASTRO publishes two medical journals, International Journal of Radiation Oncology * Biology * Physics and Practical Radiation Oncology; developed and maintains an extensive patient website, www.rtanswers.org; and created the Radiation Oncology Institute, a nonprofit foundation to support research and education efforts around the world that enhance and confirm the critical role of radiation therapy in improving cancer treatment. To learn more about ASTRO, visit www.astro.org

Association of Community Cancer Centers
The Association of Community Cancer Centers (ACCC) promotes the entire continuum of quality cancer care for our patients and our communities. Since 1974, ACCC has been helping oncology professionals adapt to the complex changes of delivering quality cancer care.

ACCC members rely on the Association to bring them information on cancer program management, reimbursement issues, legislative and regulatory changes at the state and national levels, community cancer program standards, NCI-funded community clinical research, hospital alliances and physician relationships, and more.

Approximately 20,000 cancer care professionals from 2,000 hospitals and practices nationwide are members of ACCC. It is estimated that 60 percent of the nation’s cancer patients are treated by a member of ACCC.
American Society of Clinical Oncology

The American Society of Clinical Oncology (ASCO) promotes and provides for lifelong learning for oncology professionals; cancer research; an improved environment for oncology practice; access to quality cancer care; a global network of oncology expertise; and educated and informed patients with cancer. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation, which funds ground-breaking research and programs that make a tangible difference in the lives of people with cancer.

Bladder Cancer Action Network

The Bladder Cancer Action Network (BCAN) mission is to increase public awareness about bladder cancer; to advance bladder cancer research; and, to provide educational and support services for the bladder cancer community.

Founded in 2005, BCAN is the only national organization devoted to advancing bladder cancer research and supporting those touched by the disease. Through a comprehensive program of research, education and advocacy, BCAN is the leading voice for bladder cancer. For more information, visit www.bcan.org

CancerCare®

Founded in 1944, CancerCare® is the leading national organization providing free, professional support services and information to help people manage the emotional, practical and financial challenges of cancer. Our comprehensive services include counseling and support groups over the phone, online and in-person, educational workshops, publications and financial and co-payment assistance. All CancerCare services are provided by oncology social workers and world-leading cancer experts.

CancerCare programs and services help 170,000 people each year. We distribute 800,000 publications and welcome 1.5 million website visits annually. In the past year, CancerCare provided more than $22.3 million in financial assistance. The size and scope of CancerCare has grown tremendously since 1944, but it has never wavered from its mission of providing help and hope to people affected by cancer.

Cancer Support Community

As the largest professionally led nonprofit network of cancer support worldwide, the Cancer Support Community (CSC) is dedicated to ensuring that all people impacted by cancer are empowered by knowledge, strengthened by action and sustained by community. CSC achieves its mission through three areas: direct service delivery, research and advocacy. The organization includes an international network of affiliates that offer the highest quality social and emotional support for people impacted by cancer, as well as a community of support available online and over the phone. The Research and Training Institute conducts cutting-edge psychosocial, behavioral and survivorship research. CSC furthers its focus on patient advocacy through its Cancer Policy Institute, informing public policy in Washington, D.C. and across the nation. For more information, please call the toll-free Cancer Support Helpline at 888-793-9355, or visit www.CancerSupportCommunity.org. So that no one faces cancer alone.
C-Change

C-Change is the only organization that assembles cancer leaders from across the three sectors—private, public, and not-for-profit—and from across the cancer continuum. C-Change was founded in 1998 by former President George H. W. Bush along with Barbara Bush and Senator Dianne Feinstein. Today C-Change has more than 500 strategic members and partners from cancer related institutions, government agencies, and corporate entities, and Duke University Men’s Basketball Coach, Mike Krzyzewski, serves as honorary chair. Our mission is to eliminate cancer as a major public health problem at the earliest possible time by leveraging the expertise and resources of our unique multi-sector membership. www.c-changetogether.org.

Chris4Life

The principal goal of Chris4Life Colon Cancer Foundation is to permanently eliminate the threat of colon cancer through discovery of a cure. To this end, we will fund cutting edge research so that the brightest minds and best institutions are empowered to cure colon cancer for good. Until then, Chris4Life Colon Cancer Foundation is committed to significantly improving the treatment experience for patients and caregivers, and to dramatically raise awareness about colon cancer in general. Chris4Life will utilize health and wellness as a means of integrating the mind, body and spirit in our approach. Working together we will build a culture of care and foster relationships with research institutions, advocacy groups, the health care community, and the general public.

Colon Cancer Alliance

The Colon Cancer Alliance is the nation’s largest colon cancer specific nonprofit organization. Our mission is to knock colon cancer out of the top three cancer killers. We are doing this by championing prevention, funding cutting-edge research and providing the highest quality patient support services. Read more information about the Colon Cancer Alliance at www.ccalliance.org.

Community Oncology Alliance

The Community Oncology Alliance (COA), a nonprofit organization, is the leader in advocating for patients and their providers in the community cancer care setting, where almost 70 percent of Americans with cancer are treated. The mission of COA is to strive that cancer patients receive quality, affordable and accessible cancer care, in their own communities, that is physician directed. COA has pioneered public policy on the Oncology Medical Home (OMH) and payment reform for cancer care, and provides resources for community oncology practices to become OMHs. COA members have testified before both chambers of Congress, appeared on television and are quoted extensively in the press on topics ranging from Medicare policy to cancer care delivery. Among other initiatives, COA maintains active networks of patient advocates (CPAN), practice administrators (CAN), and pharmacy personnel (COPA) dedicated to enhancing community cancer care. More information can be found at www.CommunityOncology.org and www.MedicalHomeOncology.org.
Friends of Cancer Research

Friends of Cancer Research is our country's leading voice in advocating for policies and solutions that will get treatments to patients in the safest and quickest way possible.

Friends of Cancer Research (Friends) develops groundbreaking partnerships and creates a more open dialogue among both public and private sectors and tears down the barriers that stand in the way of conquering cancer. By collaborating with premier academic research centers, professional societies and other advocacy organizations, Friends is able to accelerate innovation.

Global Colon Cancer Association

The Global Colon Cancer Association (GCCA) is the voice for the millions of colon cancer (CRC) patients worldwide. We advocate for patient centered policy around the globe to ensure increased awareness and screening, access to quality medical treatments and help our member organizations collaborate, innovate and leverage the full potential of effectuating change. The GCCA also supports the creation of new patient advocacy groups in developing areas which have no CRC organizations. The GCCA unites all stakeholders in the battle against this disease with one unified voice.

Leukemia & Lymphoma Society

The mission of The Leukemia & Lymphoma Society (LLS) is to cure leukemia, lymphoma, Hodgkin’s disease and myeloma, and improve the quality of life of patients and their families.

LLS exists to find cures and ensure access to treatments for blood cancer patients. We are the voice for all blood cancer patients and we work to ensure access to treatments for all blood cancer patients.
Lungevity
We focus on research because the link between research spending and improved survival is clear. Survival rates have dramatically improved for colorectal, breast and prostate cancers over the last several decades in step with the exponential growth in their research spending. Our goal is to accelerate progress for lung cancer in the same way, in order to dramatically improve on the current 17 percent five-year survival rate.

To date, Lungevity has funded 110 research projects at 57 institutions in 23 states. Lungevity research investments focus on early detection, because survival rates rise when lung cancer is detected while still localized. We also focus on more effective treatment approaches—getting the right treatment to the right patient at the right time to help people with lung cancer live longer and better.

Our projects are translational, moving basic research from the lab to patient treatment. We fund the projects most likely to have the greatest benefit for patients in the near term. Thanks to our scientific advisory board—a group that includes leaders in early detection, genomics, proteomics, immunotherapy, biostatistics and thoracic surgery—research project applications are rigorously reviewed in a robust, transparent process and then funded projects are carefully monitored. Through ongoing work with researchers across the various institutions, lungevity maximizes the progress and impact of ongoing studies.

Lungevity also provides a community of empowerment, support and hope for everyone affected by lung cancer through our extensive educational resources, online peer-to-peer support and in-person survivorship programs, as well as more than 80 grassroots awareness and fundraising events held from coast to coast each year.

Multiple Myeloma Research Foundation
The Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a 501(c)(3) non-profit organization by twin sisters Karen Andrews and Kathy Giusti, soon after Kathy’s diagnosis with multiple myeloma, an incurable blood cancer. The Multiple Myeloma Research Foundation is the world’s number one private funder of multiple myeloma research. Since its inception the MMRF has tripled the life expectancy of patients, launched over 60 clinical trials and has helped deliver seven new drugs to market. The MMRF has raised over $275 million dollars with nearly 90 percent of the total budget directed to research and related programming. For more information, visit themmrf.org or contact Sharon Saias at 203-652-0211.

National Patient Advocate Foundation
The National Patient Advocate Foundation (NPAF) is a national nonprofit organization that serves as the patient voice for improving access to, and reimbursement for, high-quality health care through regulatory and legislative reforms at the state and federal levels. NPAF translates the experience and needs of tens of thousands of patients who receive direct services from our companion organization each year, the Patient Advocate Foundation, into advocacy platforms focused on reducing or eliminating barriers to healthcare access for those with chronic, debilitating or life-threatening disease.
No Stomach for Cancer

Founded in 2009, No Stomach For Cancer, Inc. is a 501(c)(3) nonprofit organization whose mission is to support research and unite the caring power of people worldwide affected by stomach cancer. The organization advances awareness and education about stomach cancer, including Hereditary Diffuse Gastric Cancer (HDGC), provides a support network for affected families, and supports research for screening, early detection, treatment, and prevention of stomach cancer. Headquartered in Madison WI and serving families across the globe, No Stomach For Cancer is a worldwide thought leader in stomach cancer awareness and education. For more information, please visit www.nostomachforcancer.org.

Oncology Nursing Society

The Oncology Nursing Society (ONS) is a professional association of more than 35,000 members committed to promoting excellence in oncology nursing and the transformation of cancer care.

Since 1975, ONS has provided a professional community for oncology nurses, developed evidence-based education programs and treatment information, and advocated for patient care, all in an effort to improve quality of life and outcomes for patients with cancer and their families. Together, ONS and the cancer community seek to reduce the risks, incidence and burden of cancer by encouraging healthy lifestyles, promoting early detection and improving the management of cancer symptoms and side effects throughout the disease trajectory.

Ovarian Cancer National Alliance

The Ovarian Cancer National Alliance is a powerful voice for everyone touched by ovarian cancer. We connect survivors, women at risk, caregivers and health providers with the information and resources they need. We ensure that ovarian cancer is a priority for lawmakers and agencies in Washington, D.C., and throughout the country. We help our community raise their voices on behalf of every life that has been affected by this disease.

Prevent Cancer Foundation

The mission of the Prevent Cancer Foundation is saving lives through cancer prevention and early detection. Our vision is to Stop Cancer Before It Starts! Founded in 1985, the Prevent Cancer Foundation has been a leader in cancer prevention and early detection. As the only nonprofit in the United States solely focused on cancer prevention and early detection, the Foundation has been referred to as “the candle that ignited a bonfire” in the field of prevention. Investing more than $138 million over the past 30 years, the Prevent Cancer Foundation has always focused its resources on cancers that can be prevented in many instances through healthy lifestyle choices or early detection.
Sarcoma Foundation of America

The Sarcoma Foundation of America (SFA), a 501(c)(3) nonprofit charitable organization, advocates for increased research to find new and better therapies with which to treat patients with sarcoma. The organization raises money to privately fund grants for researchers and conducts education and advocacy efforts on behalf of sarcoma patients. The SFA also interacts with public, private for-profit and private nonprofit entities to educate and raise awareness about the treatment needs of sarcoma patients. More information about the SFA can be found at www.curesarcoma.org.

Susan G. Komen

Susan G. Komen is the world’s largest breast cancer organization, funding more breast cancer research than any other nonprofit while providing real-time help to those facing the disease. Since its founding in 1982, Komen has funded more than $847 million in research and provided $1.8 billion in funding to screening, education, treatment and psychosocial support programs serving millions of people in more than 30 countries worldwide. Komen was founded by Nancy G. Brinker, who promised her sister, Susan G. Komen, that she would end the disease that claimed Suzy’s life. Visit www.komen.org or call 1-877 GO KOMEN. Connect with us on social at www.komen.org/social.

Women Against Prostate Cancer

Women Against Prostate Cancer (WAPC) connects an expanding national grassroots network of volunteers that provides support for women and their families affected by prostate cancer through access to resources and innovative programming. WAPC is also a tool for women to harness the power of their voices to advance national and state-based educational, media and public policy efforts.

WAPC’s mission is based on three elements—uniting, advocating and educating the millions of women and their families affected by prostate cancer. The education component of our mission is multifaceted and includes efforts to inform about the prevention and treatment of prostate cancer through public awareness campaigns, educational symposia, and provide support and educational information and resources to the millions of caretakers and their families affected by this disease. WAPC advocates prostate cancer education, public awareness, screenings, legislation and treatment options.